Last update Jan. 9, 2023

Ganirelix Acetate

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Cetrorelix is a synthetic decapeptide antagonist of gonadorelin (gonadotropin-releasing hormone) that is used to prevent luteinizing hormone surges and premature ovulation in women undergoing ovarian stimulation treatment for assisted reproduction in cases of infertility. Subcutaneous administration.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its pharmacokinetic data (high percentage of protein binding, high molecular weight and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.

Its low oral bioavailability makes it difficult for it to pass to the infant’s plasma via ingested breast milk as, due to its protein nature, it degrades in the gastrointestinal tract and is not absorbed.

See below the information of this related product:


We do not have alternatives for Ganirelix Acetate.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Ganirelix Acetate in other languages or writings:

  • Ганиреликса Ацетат (Cyrillic)
  • ガニレリクス酢酸塩 (Japanese)
  • N-Acetyl-3-(2-naphthyl)-d-alanyl-p-chloro-d-phenylalanyl-3-(3-pyridyl)-d-alanyl-l-seryl-l-tyrosyl-N6-(N,N′-diethylamidino)-d-lysyl-l-leucyl-N6-(N,N′-diethylamidino)-l-lysyl-l-prolyl-d-alaninamide acetate (Chemical name)
  • C80H113ClN18O13,2C2H4O2 (Molecular formula)
  • H01CC01 (ATC Code/s)


Ganirelix Acetate belongs to this group or family:


Main tradenames from several countries containing Ganirelix Acetate in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 1.691 daltons
Protein Binding 82 %
VD 0.6 l/Kg
pKa 9.5 -
Tmax 1 - 2 hours
13 - 16 hours


  1. Merck. Ganirelix. Drug Summary. 2018 Full text (in our servers)
  2. Ganirelix Ficha técnica 2013 Full text (in our servers)
  3. Ganirelix Drug Summary 2013 Full text (in our servers)
  4. EMA. Ganirelix. Ficha técnica, 2010 Full text (in our servers)
  5. Oberyé JJ, Mannaerts BM, Kleijn HJ, Timmer CJ. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril. 1999 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM